Prime Medicine, Inc.
PRME · XNASCIK 1894562fmd_02N6SM94Z2APEJDNNGF7J0QR6YManufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jan 01, 2020 to Sep 30, 2026, 24 periods
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Total revenues | 5 | 0 | 0 | 0 | 3 | 5 |
| Research and development | 3 | 71 | 87 | 148 | 155 | 161 |
| Total operating expenses | 6 | 84 | 117 | 205 | 205 | 213 |
| Operating income | (1) | (84) | (117) | (205) | (202) | (208) |
| Interest and investment income | – | – | – | 3 | 4 | 4 |
| Other non-operating income (expense) | (1) | (81) | (6) | 6 | 7 | 7 |
| Income tax expense | 2 | (0) | (1) | (0) | 0 | 0 |
| Net income | (3) | (165) | (122) | (198) | (196) | (201) |
| Net income to common shareholders | (5) | (184) | (142) | (198) | (196) | (201) |